PT - JOURNAL ARTICLE AU - Cao, Lirong AU - Lou, Jingzhi AU - Zheng, Hong AU - Zhao, Shi AU - Mok, Chris Ka Pun AU - Yi Chan, Renee Wan AU - Chong, Marc Ka Chun AU - Chen, Zigui AU - Yi Wong, Eliza Lai AU - Chan, Paul Kay Sheung AU - Zee, Benny Chung-Ying AU - Yeoh, Eng Kiong AU - Wang, Maggie Haitian TI - Rapid evaluation of COVID-19 vaccine effectiveness against VOC/VOIs by genetic mismatch AID - 10.1101/2021.04.22.21254079 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.22.21254079 4099 - http://medrxiv.org/content/early/2021/11/26/2021.04.22.21254079.short 4100 - http://medrxiv.org/content/early/2021/11/26/2021.04.22.21254079.full AB - Timely evaluation of the protective effects of COVID-19 vaccines is challenging but urgently needed to inform the pandemic control planning. Based on vaccine efficacy/effectiveness (VE) data of 11 vaccine products and 297,055 SARS-CoV-2 sequences collected in 20 regions, we analyzed the relationship between genetic mismatch of circulating viruses against the vaccine strain and VE. Variations from technology platforms are controlled by a mixed-effects model. We found that the genetic mismatch measured on the RBD is highly predictive for vaccine protection and accounted for 72.0% (p-value < 0.01) of the VE change. The NTD and S protein also demonstrate significant but weaker per amino acid substitution association with VE (p-values < 0.01). The model is applied to predict vaccine protection of existing vaccines against new genetic variants and is validated by independent cohort studies. The estimated VE against the delta variant is 79.3% (95% prediction interval: 67.0 – 92.1) using the mRNA platform, and an independent survey reported a close match of 83.0%; against the beta variant (B.1.351) the predicted VE is 53.8% (95% prediction interval: 39.9 – 67.4) using the viral-vector vaccines, and an observational study reported a close match of 48.0%. Genetic mismatch provides an accurate prediction for vaccine protection and offers a rapid evaluation method against novel variants to facilitate vaccine deployment and public health responses.Competing Interest StatementM.H.W and B.C.Y.Z are shareholders of Beth Bioinformatics Co., Ltd. B.C.Y.Z is a shareholder of Health View Bioanalytics Ltd. All other authors declare no competing interests.Funding StatementThis work was partially supported by the Health and Medical Research Fund, the Food and Health Bureau, the Government of the Hong Kong Special Administrative Region [COVID190103, INF-CUHK-1], the National Natural Science Foundation of China [31871340, 71974165], and the Chinese University of Hong Kong Grant [PIEF/Ph2/COVID/06, 4054600].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval or individual consent was not applicable.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work are publicly available.